#chemoradiotherapy

Introduction: Although several studies in esophageal squamous cell carcinoma (ESCC) have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pathological complete response (pCR) rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate…

Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study Summary This phase II study explored the efficacy of adding sintilimab (an anti-PD-1 immunotherapy) to standard neoadjuvant chemoradiotherapy (nCRT) for patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) rectal cancer…

One Day at a Time

Things are now in motion for the first rounds of chemoradiotherapy to work. The elimination state begins and I feel fair to middling this morning. I’m going to try to do some symbolic cleaning up in my office once I get some more bugs fixed and then try to make Leslie Davenport’s class. Leslie’s class was taught by an art therapist this time and we built worry dolls. My doll was named Homer and…

Durvalumab May Improve Survival of Non-small Cell Lung Cancer Patients

Patients with non-small cell lung cancer survive longer when their therapy includes durvalumab following platinum-based chemoradiotherapy, reports a new study. The findings of the study are published in the New England Journal of Medicine.

Durvalumab (Imfinzi®) is an immune checkpoint inhibitor that received United States Food and Drug Administration (FDA) approval in February as a new…